Description

Buy Ostarine MK-2866

Alson known as Enobosarm, is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for the treatment of conditions such as muscle wasting and osteoporosis, formerly under development by Merck & Company. Buy Ostarine MK-2866

Chemistry of Ostarine MK-2866

According to a 2009 paper authored by GTx, “Readers are cautioned to note that the name Ostarine MK-2866 is often mistakenly linked to the chemical structure of [S-4], which is also known as andarine. The chemical structure of Ostarine MK-2866 has not been publicly disclosed. A 2009 review stated “Recently, GTx disclosed that compound 5 had advanced into clinical trials. The patent application described detailed data in an initial proof-of-concept Phase IIa clinical trial. It is not explicitly stated that compound 5 is Ostarine MK-2866.

History

GTx Incorporated was founded in Memphis in 1997 and licensed rights to enobosarm from the University of Tennessee Research Foundation; the SARM compounds were invented by James T. Dalton, Duane D. Miller, Karen A. Veverka and their research teams at The Ohio State University, the University of Tennessee and GTx, respectively.

By 2007 enobosarm was in a Phase II trial, and that year GTx signed an exclusive license agreement for its SARM program with Merck & Co. The companies ended the deal in 2010. Buy Ostarine MK-2866

In August 2013 GTx announced that enobosarm had failed in two Phase III clinical trials to treat wasting in people with lung cancer.The company had invested around $35 million in the development of the drug. The company said at that time that is planned to pursue approval of enobosarm in Europe; the company was also still developing GTx-758 for castration-resistant prostate cancer.

In 2016 GTx began Phase II trials, to see if enosobarm might be effective to treat stress urinary incontinence in women. If you have any other question feel free to contact us.